Prenatal Exome Sequencing For Fetal Structural Anomalies
A detailed ultrasound can reveal that a fetus has an unusual heart, brain, kidney, skeletal or other organ development. In some pregnancies, the scan suggests a recognisable syndrome; in others, the pattern is too broad to identify a cause. Prenatal exome sequencing can examine many genes at once and may clarify why structural anomalies have occurred.
The test is most useful when it is offered alongside careful imaging, genetic counselling and shared decision-making. It does not replace ultrasound, chromosomal testing or specialist review. For families in Australia, the pathway may involve a maternal-fetal medicine unit, a clinical geneticist, a genetic counsellor and a laboratory operating within relevant quality and privacy requirements.
What The Test Examines
The exome is the portion of human DNA that contains most protein-coding regions. Although it represents only a small percentage of the genome, it includes many genes known to influence fetal development. Sequencing may identify a pathogenic variant associated with a condition that explains one or more abnormalities seen on ultrasound.
Structural anomalies can involve a single organ or several body systems. Examples include congenital heart disease, ventriculomegaly, renal abnormalities, shortened long bones, diaphragmatic hernia and multiple congenital differences. The likelihood of finding an explanation generally increases when anomalies affect more than one system or form a recognisable pattern.
Exome sequencing is different from a chromosome test. Karyotyping and chromosomal microarray look for extra, missing or rearranged chromosomal material, while exome analysis focuses mainly on changes within individual genes. These tests answer different questions and may be used in sequence or together, depending on the clinical picture.
The former congress setting associated with this subject brought together specialists in perinatal and neonatal medicine, fetal therapy and research. Its archived scientific context remains available through the FAOPS 2020 website, which records the meeting’s focus on fetal and newborn care.
When It Adds Value
Prenatal exome sequencing is commonly considered when a high-quality ultrasound shows one or more significant anomalies and chromosomal microarray has not provided an answer. It can be especially informative for multiple anomalies, severe skeletal findings, abnormal brain development or a suspected monogenic syndrome.
The test may also be discussed when a family has a previous child or pregnancy affected by a condition that could have a genetic cause. A family history of developmental disability, unexplained infant death or recurrent fetal abnormalities can influence the assessment. The decision should be based on the whole clinical picture rather than a single ultrasound feature.
A result can assist with pregnancy management, delivery planning and newborn treatment. For example, knowing that a fetus has a condition associated with progressive lung disease, heart complications or metabolic problems may help clinicians arrange care at an appropriate tertiary centre. It can also inform recurrence-risk counselling for future pregnancies.
The result is not guaranteed to change management. Some families value an explanation even when treatment options remain limited, while others may find uncertain information difficult to use. Counselling before testing should address both the possible benefits and the emotional consequences of receiving a result.
How Sampling And Analysis Work
DNA for prenatal testing is usually obtained through chorionic villus sampling or amniocentesis. Chorionic villus sampling samples placental tissue earlier in pregnancy, whereas amniocentesis uses amniotic fluid later. Both are invasive procedures with a small risk of complications, so timing and suitability require discussion with a fetal medicine specialist.
In some cases, laboratories recommend sequencing the fetus and both biological parents, known as a trio analysis. Comparing the three samples helps identify variants that are new in the fetus and may therefore explain the anomaly. It also improves interpretation of variants inherited from a parent who may have few or no symptoms.
The laboratory classifies genetic changes according to evidence from published research, databases, population data and the clinical findings. A pathogenic or likely pathogenic variant may provide a diagnosis. A variant of uncertain significance generally should not be used alone to make major decisions about pregnancy or newborn treatment.
Turnaround times vary by laboratory and urgency. A rapid analysis may be considered when the result could affect imminent delivery or neonatal care, while standard testing may take longer. Families should ask what is included, whether parental samples are covered, how results will be reported and whether reanalysis is available as knowledge changes.
Interpreting Results With Families
A positive result can explain the ultrasound findings, identify likely complications and indicate whether other relatives should seek advice. Some conditions have a wide range of outcomes, so a genetic diagnosis rarely predicts every aspect of a child’s future. The care team should translate technical findings into practical information about pregnancy, birth and early childhood.
A negative result does not prove that the fetus has no genetic condition. Exome sequencing may miss changes in regions it does not examine, repeat expansions, some copy-number changes, mitochondrial disorders or variants that science cannot yet interpret. The original ultrasound diagnosis may still be valid even when no molecular cause is found.
Families may receive an uncertain result, particularly when the fetal findings are unusual or incomplete. Follow-up imaging, postnatal examination, parental testing and future research can sometimes clarify its meaning. It is important to distinguish a finding that is genuinely uncertain from a result that has been interpreted as reassuring.
In Australia, consent discussions also need to cover secondary findings and data handling. Laboratories and clinical services should explain whether unrelated health risks might be reported, how samples are stored and who can access genetic information. The Privacy Act 1988 and state and territory health-record rules form part of the broader privacy framework, although specific clinical policies differ.
Australian Care Pathways
A pregnant patient may enter the pathway through a general practitioner, obstetrician, sonographer or hospital antenatal clinic. Public tertiary services in Sydney, Melbourne, Brisbane, Perth, Adelaide and other regional centres often coordinate fetal medicine, genetics and neonatal care. People living in rural and remote areas may use telehealth, travel assistance schemes or local ultrasound services before attending a metropolitan unit.
Australia’s public and private systems can produce different costs and waiting times. Medicare may cover parts of specialist care when eligibility and referral requirements are met, but prenatal exome sequencing is not automatically free in every setting. Private genetic testing may involve out-of-pocket expenses, and families should request a written estimate before consenting.
NIPT is widely available through the private market and is commonly used to screen for selected chromosomal conditions. It is a screening test, not a diagnostic test, and it does not replace targeted investigation of a structural anomaly. A concerning NIPT result usually requires diagnostic testing, while a normal NIPT result does not exclude single-gene disorders.
Counselling should also reflect Australian law and local practice. Termination regulations vary between states and territories, and gestational limits, approval processes and access pathways are not identical across the country. Clinicians need to provide balanced information without assuming that a genetic diagnosis leads to one predetermined decision.
Limits, Ethics And Practical Decisions
Prenatal exome sequencing can uncover information about the fetus, the parents and sometimes wider family members. A result may reveal that a parent carries a variant associated with an adult-onset condition, or it may identify non-paternity or consanguinity unexpectedly. Pre-test counselling should explain these possibilities in clear, non-technical language.
Testing can also influence decisions about delivery location and fetal therapy. A molecular diagnosis may make an invasive procedure less appropriate, or it may help identify fetuses likely to benefit from specialist intervention. Families can review how genetic information fits with surgical options through resources discussing fetal surgery indications, while recognising that an individual plan must come from the treating team.
The ethical balance includes the fetus’s interests, parental values, the likely severity of the condition and the reliability of available evidence. Clinicians should avoid presenting uncertain predictions as definite outcomes. A multidisciplinary meeting can bring together fetal medicine, genetics, neonatology, paediatric subspecialists, surgery, nursing and psychosocial support.
| Result or finding | What it may clarify | Usual next considerations |
|---|---|---|
| Pathogenic variant explaining the anomaly | Diagnosis, expected complications and recurrence risk | Specialist counselling, targeted imaging and delivery planning |
| Likely pathogenic variant with limited evidence | A probable explanation, but with uncertainty | Review the evidence, consider parental testing and discuss limits |
| Variant of uncertain significance | A genetic change whose meaning is not established | Avoid using it alone for major decisions; arrange follow-up |
| No significant finding | No cause identified by the test | Continue clinical assessment and consider reanalysis or other testing |
| Unexpected parental or secondary finding | Health information beyond the fetal anomaly | Discuss privacy, family implications and appropriate specialist referral |
Building A Decision-Ready Service
A safe service begins with a clear referral pathway and access to high-quality ultrasound. The referral should include the gestational age, imaging findings, previous test results, relevant family history and the questions the family wants answered. A genetics professional can then choose the most suitable test rather than ordering exome sequencing automatically.
The following practices can make counselling and coordination more consistent:
- Offer pre-test counselling before invasive sampling whenever possible.
- Use trio sequencing when parental samples are available and clinically appropriate.
- Record the ultrasound phenotype in enough detail for laboratory interpretation.
- Explain uncertain, negative and unexpected results before testing begins.
- Arrange post-test review, family counselling and reanalysis when new evidence emerges.
Australian services should also plan for practical barriers. A family from regional Queensland or Western Australia may need accommodation and time away from work for appointments. Telehealth can reduce travel, but it cannot replace every examination or face-to-face counselling session. Clear communication about Medicare, private fees, consent forms and result timing helps families make informed choices.
The strongest pathway links prenatal diagnosis with neonatal and paediatric services. When a result predicts respiratory, cardiac, neurological or metabolic complications, the birth plan can be adjusted before labour begins. Families should receive one coordinated explanation of the evidence, realistic options and available support rather than disconnected opinions from multiple clinics.
Prenatal exome sequencing is most valuable when it answers a clinically important question and is interpreted in the context of skilled imaging and compassionate care. Families considering testing should request referral to a fetal medicine or genetics team, ask how the result could affect management, and ensure that consent covers both known possibilities and remaining uncertainty.
